Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study.
BKV
Everolimus
Kidney transplantation
mTOR inhibitors
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
22
01
2020
accepted:
06
06
2020
pubmed:
14
6
2020
medline:
19
8
2021
entrez:
14
6
2020
Statut:
ppublish
Résumé
There is no specific therapy for polyoma BK virus nephropathy (BKVN) in kidney transplant recipients, a condition associated with poor outcomes. Everolimus showed promising antiviral effects, but data from prospective studies are limited. Therefore, we converted ten consecutive kidney transplant recipients with biopsy-proven BKVN from standard exposure Calcineurin inhibitors and Mycophenolate to Everolimus and reduced exposure Calcineurin inhibitors. Ten patients not administered Everolimus, on reduced exposure Calcineurin inhibitor and halved MPA doses served as controls. All kidney transplant recipients continued steroid therapy. Each patient underwent kidney graft biopsy, BKV replication by PCR, and de novo DSA determination. During a 3-year follow-up no graft loss occurred in kidney transplant recipients on Everolimus but it was observed in 5/10 controls (P = 0.032). eGFR improved on Everolimus and worsened in controls (between group difference + 25.6 ml/min/1.73 m
Identifiants
pubmed: 32533451
doi: 10.1007/s40620-020-00777-2
pii: 10.1007/s40620-020-00777-2
doi:
Substances chimiques
Calcineurin Inhibitors
0
Immunosuppressive Agents
0
Everolimus
9HW64Q8G6G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-538Références
Sawinski D, Goral S (2015) BK virus infection: an update on diagnosis and treatment. Nephrol Dial Transplant 30:209–217
doi: 10.1093/ndt/gfu023
Hirsch HH, Randhawa P (2013) AST infectious diseases community of practice. BK polyomavirus in solid organ transplantation. Am J Transplant 13(suppl 4):179–188
doi: 10.1111/ajt.12110
Reischig T, Kacer M, Hes O et al (2019) Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. Am J Transplant. https://doi.org/10.1111/ajt.15507
doi: 10.1111/ajt.15507
pubmed: 31529778
Cucchiari D, Ríos J, Molina-Andujar A et al (2020) Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice. J Nephrol 33(3):601–610
doi: 10.1007/s40620-019-00675-2
Paoletti E, Citterio F, Corsini A et al (2020) Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review. J Nephrol 33(1):69–82
doi: 10.1007/s40620-019-00609-y
Bowman LJ, Brueckner AJ, Doligalski CT (2018) The role of mTOR inhibitors in the management of viral infections: a review of current literature. Transplantation 102:S50–S59
doi: 10.1097/TP.0000000000001777
Ponticelli C, Glassock RJ (2019) Prevention of complications from use of conventional immunosuppressants: a critical review. J Nephrol 32:851–870
doi: 10.1007/s40620-019-00602-5
Jacobi J, Prignitz A, Büttner M et al (2013) BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition. BMC Nephrol 14:207
doi: 10.1186/1471-2369-14-207
Tedesco-Silva H, Pascual J, Viklicky O, TRANSFORM Investigators et al (2019) Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. https://doi.org/10.1097/TP.0000000000002626
doi: 10.1097/TP.0000000000002626
pubmed: 30801548
Sommerer C, Suwelack B, Dragun D, ATHENA Study Group et al (2019) An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int 96:231–244
doi: 10.1016/j.kint.2019.01.041
Wojciechowski D, Chandran S, Webber A, Hirose R, Vincenti F (2017) Mycophenolate mofetil withdrawal with conversion to everolimus to treat BK virus infection in kidney transplant recipients. Transplant Proc 49:1773–1778
doi: 10.1016/j.transproceed.2017.06.030
Polanco N, González Monte E, Folgueira MD et al (2015) Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant Proc 47:57–61
doi: 10.1016/j.transproceed.2014.11.008
Wali RK, Drachenberg C, Hirsch HH et al (2004) BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 78:1069–1073
doi: 10.1097/01.TP.0000142127.84497.50
Schwarz A, Linnenweber-Held S, Heim A et al (2012) Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation. Transplantation 94:396–402
doi: 10.1097/TP.0b013e31825a505d
Haas M, Sis B, Racusen LC et al (2014) Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 14:272–283
doi: 10.1111/ajt.12590
Nickeleit V, Singh HK, Randhawa P et al (2018) The Banff Working Group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J Am Soc Nephrol 29:680–693
doi: 10.1681/ASN.2017050477
Nocera A, Tagliamacco A, Cioni M et al (2017) Kidney intragraft homing of de novo donor-specific HLA antibodies is an essential step of antibody-mediated damage but not per se predictive of graft loss. Am J Transplant 17:692–702
doi: 10.1111/ajt.14000
Greene T, Teng CC, Inker LA et al (2014) Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study. Am J Kidney Dis 64:867–879
doi: 10.1053/j.ajkd.2014.08.019
Mallat SG, Tanios BY, Itani HS et al (2017) CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 12:1321–1336
doi: 10.2215/CJN.13221216
Dharnidharka VR, Cherikh WS, Abbott KC (2009) An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 87:1019–1026
doi: 10.1097/TP.0b013e31819cc383
Araki K, Turner AP, Shaffer VO, Gangappa S et al (2009) mTOR regulates memory CD8 T-cell differentiation. Nature 460:108–112
doi: 10.1038/nature08155
Hirsch HH, Yakhontova K, Lu M, Manzetti J (2016) BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12. Am J Transplant 16:821–832
doi: 10.1111/ajt.13541
Egli A, Köhli S, Dickenmann M, Hirsch HH (2009) Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation 88:1161–1168
doi: 10.1097/TP.0b013e3181bca422
Li YJ, Wu HH, Weng CH et al (2012) Cyclophilin A and nuclear factor of activated T cells are essential in cyclosporine-mediated suppression of polyomavirus BK replication. Am J Transplant 12:2348–2362
doi: 10.1111/j.1600-6143.2012.04116.x
Acott PD, O'Regan PA, Lee SH, Crocker JF (2008) In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl Infect Dis 10:385–390
doi: 10.1111/j.1399-3062.2008.00330.x
Egli A, Dumoulin A, Köhli S, Hirsch HH (2009) Polyomavirus BK after kidney transplantation—role of molecular and immunological markers. Trends Transplant 3:85–102
Bemelman FJ, de Fijter JW, Kers J et al (2017) Early conversion to prednisolone/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial. Am J Transplant 17:1020–1030
doi: 10.1111/ajt.14048
Perbos E, Juinier E, Guidicelli G et al (2014) Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors. Clin Transplant 28:1054–1060
doi: 10.1111/ctr.12418
Sawinski D, Trofe-Clark J (2018) BK virus nephropathy. Clin J Am Soc Nephrol 13:1893–1896
doi: 10.2215/CJN.04080318